Chimeric Peptides for Anti-Toxoplasma Gondii IgM Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current serological tests for detecting anti-T. gondii IgM antibodies face challenges such as low inter-assay reproducibility, laborious and expensive production, and low immunoreactivity, limiting their effectiveness in diagnosing acute toxoplasmosis.
Innovation Solution
Designing and synthesizing T. gondii IgM-specific chimeric peptides and evaluating their diagnostic utility in an immunoassay, including the use of peptide microarrays and synthetic chimeric peptides like 3a6c, to enhance assay performance and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If T. gondii lysate antigens are used for detection, then the assay can detect anti-T. gondii IgM antibodies, but the inter-assay reproducibility is low and standardization is difficult
Solution Approach 1:
The patent segments the complex T. gondii lysate antigen into individual recombinant antigens (rSAG1, rSAG2, rGRA1, rGRA2, rGRA6, rROP1, rROP2). Each recombinant antigen is produced separately and characterized individually, allowing for precise standardization and consistent inter-assay reproducibility while maintaining the ability to detect anti-T. gondii IgM antibodies
Solution Approach 2:
The patent changes the production parameters from traditional lysate preparation to recombinant protein expression systems. By controlling expression conditions, purification parameters, and antigen concentration standards, the patent achieves high inter-assay reproducibility and easy standardization while preserving diagnostic sensitivity
2Ease of manufacture
If purified recombinant antigens are used, then production becomes less laborious and expensive, but immunoreactivity is low
Solution Approach 1:
The patent creates a composite diagnostic approach by combining multiple purified recombinant antigens (rSAG1, rSAG2, rGRA1, rGRA2, rGRA6, rROP1, rROP2) into a multi-antigen assay system. This composite strategy compensates for the low immunoreactivity of individual recombinant antigens while maintaining the ease and low cost of recombinant production, achieving both manufacturability and diagnostic reliability
3Reliability
If traditional T. gondii lysate antigens are used, then high immunoreactivity is achieved, but production is laborious and expensive
Solution Approach 1:
The patent extracts the essential immunogenic components from the complex T. gondii lysate by producing specific recombinant antigens (rSAG1, rSAG2, rGRA1, rGRA2, rGRA6, rROP1, rROP2) that correspond to key surface and secreted proteins. This extraction approach captures the high immunoreactivity of native antigens while eliminating the laborious and expensive procedures required for traditional lysate preparation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of T. gondii IgM-specific chimeric peptides improves the detection of anti-T. gondii IgMs, offering enhanced sensitivity and specificity, and potentially replacing traditional T. gondii lysate antigens in diagnostic assays.
Implementation Method 1
The use of T. gondii IgM-specific chimeric peptides improves the detection of anti-T. gondii IgMs
Data Source
AI summary
The present invention provides compounds, methods for their preparation, methods for their use and compositions containing them, which are suitable for industrial application in the pharmaceutical and diagnostic/prognostic field, particularly for the detection and diagnosis of Toxoplasma gondii infections, as well as for the treatment and prevention of said infections.